Close Menu

Qiagen: Thierry Bernard

Mar 25, 2020

Qiagen said this week that it has named Thierry Bernard as CEO. Qiagen's board has also resolved to propose Bernard for election as CEO and managing director at the company's next annual meeting in June. Bernard, who is also senior VP and head of molecular diagnostics at Qiagen, has served as the company's interim CEO since October, when long-time CEO Peer Schatz parted ways with the company. Bernard joined Qiagen in 2015. Prior to that he was senior executive VP of worldwide commercial operations at BioMérieux, where he also managed investor relations for the greater China region.

Bernard is "an outstanding leader who has performed impressively while guiding Qiagen through a period of significant change since taking on this role on an interim basis in October 2019," Håkan Björklund, chairman of Qiagen's supervisory board, said in a statement. "He is a strong and proven leader with extensive industry expertise and deep customer relationships. Most important, he has shown the energy and skill to drive Qiagen forward and has been a key leader in achieving the agreement for Qiagen to be acquired by Thermo Fisher Scientific in a transaction that remains on track for completion in the first half of 2021."

More Like This

Dec 04, 2020

Waters: Sherry Buck, Michael Silveira

Waters announced this week that CFO Sherry Buck will step down as CFO at the end of this month. She has taken a position at a privately held firm, Waters said. Michael Silveira, currently VP and corporate controller at Waters, will assume the role of interim CFO. Waters said it is working with an executive search firm to identify a permanent CFO.

Dec 04, 2020

Rhinostics: Cheri Walker

Cheri Walker has been appointed president and CE of Rhinostics, a Cambridge, Massachusetts-based sample collection device firm. Walker has served in management roles at Invitrogen, Qiagen, Charles River Laboratories, Kailos Genetics, and most recently was senior VP of corporate development at Abcam. 

Dec 03, 2020

InterVenn Biosciences: John Leite

John Leite has become chief business officer at InterVenn Biosciences, based in South San Francisco. Previously, he was VP of oncology, market development, and product marketing for Illumina's oncology business. Prior to that, he was VP of commercial strategy and market access for Genoptix, and earlier in his career, he was a scientist at Invitrogen. Leite holds a PhD in biochemistry from the University of Pittburgh School of Medicine.

Dec 03, 2020

4basebio: Hansjörg Plaggemars, Alexander Link

Hansjörg Plaggemars has been appointed to the executive management board of 4basebio in Germany. He also resigned from the firm's supervisory board, effective Nov. 29, and is replaced by Alexander Link, who was elected as a substitute member to the board on Nov. 3.

Dec 02, 2020

Datavant: Mark Karch

Datavant has hired Mark Karch as chief commercial officer. He comes the startup health data integrator and analytics firm from IQvia, where he led software-as-a-service technology sales following that company's acquistion of Appature, where Karch had been executive VP of commercialization. Karch also was EVP of the former pharmaceutical business at Allscripts Healthcare Solutions, the health IT vendor with roots in drug repackaging.

Dec 01, 2020

Congenica: Muthu Meyyappan

Congenica has hired Muthu Meyyappan as chief commercial officer. Meyyappan will lead the UK-based company's global sales and marketing efforts from Congenica's US headquarters in Boston. He comes to Congenica from Variantyx, where he also served as CCO for Variantyx. Previous jobs include VP for advanced genomics commercial operations at Qiagen and chief business officer for Biobase, a company Qiagen acquired in 2014.

Nov 25, 2020

Interpace Biosciences: Thomas Burnell, Jack Stover

Interpace Biosciences said that current President and CEO Jack Stover will retire effective Dec. 31, 2020, and will be replaced as president and CEO by Thomas Burnell. Stover will also step down from the company's board of directors once Burnell joins the company and is appointed to the board, but will serve as an advisor to Interpace through the middle of 2021 to support the transition.

Burnell has previously served as president and CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories, and Eurofins Scientific. He has also previously held leadership roles with companies such as Elite One Source, Nebraska Heart Institute, and most recently the Pioneer Heart Institute.

Nov 25, 2020

Enzo Biochem: Ian Walters

Ian Walters has been appointed to the board of directors of Enzo Biochem. He is the CEO and director of Portage Biotech, a biopharmaceutical firm developing immuno-oncology treatments. Previously, he was executive director of global oncology clinical research and business development at Bristol-Myers Squibb and medical director at Millennium Pharmaceuticals. Walters holds an MBA from the Wharton School of the University of Pennsylvania and an MD from Albert Einstein College of Medicine.

Nov 23, 2020

Thermo Fisher Scientific: Alexandra Keith

Alexandra Keith has been elected to the board of directors of Thermo Fisher Scientific. She is the CEO of Procter & Gamble's global beauty business and a member of P&G's global leadership council. Over the past 30 years, she has served in a variety of roles at P&G, including in manufacturing, logistics, communications, and product innovation.

Nov 20, 2020

Congenica: Sam Roberts

Sam Roberts has been appointed as a non-executive board director of Congenica. She is the managing director of Health & Care at Legal & General, which co-led Congenica's recent $50 million Series C funding round. Previously, she was the chief executive of the Accelerated Access Collaborative, an umbrella organization for UK health innovation. She also used to be director of innovation, research, and life sciences at NHS England. Roberts holds an MBA from the Australian Graduate School of Management and a doctorate in evidence-based healthcare from the University of Oxford.

Nov 20, 2020

Omniome: Robert Wicke

Omniome has appointed Robert Wicke as CEO. He is also joining the San Diego-based sequencing technology company's board of directors. Wicke comes to Omniome from Halo Labs, where he was CEO. Previously, he held executive leadership positions at ForteBio, Pall, Molecular Devices, and Axon Instruments.

Nov 19, 2020

Icahn School of Medicine at Mount Sinai: Alison Goate

Alison Goate has been named chair of the department of genetics and genomics sciences at the Icahn School of Medicine at Mount Sinai, effective Jan. 1, 2021.

Goate is the Willard T.C. Johnson research professor of neurogenetics and a professor of genetics and genomic science, neuroscience, and neurology. Her research focuses on genetic risk factors of neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia.

She came to Mount Sinai in 2015 as founding director of the Ronald M. Loeb Center for Alzheimer's Disease and is a member of the National Academy of Medicine and a fellow of the American Association for the Advancement of Science. Goate holds a doctorate from the University of Oxford.

Nov 19, 2020

Natera: Monica Bertagnolli

Monica Bertagnolli has been appointed to the board of directors of Natera. She is a professor of surgery at Harvard Medical School and associate surgeon in the division of surgical oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. In addition, she is the CEO of Alliance Foundation Trial, a nonprofit organization that conducts international cancer clinical trials, as well as VP of the Coalition of Cancer Cooperative Groups. Bertagnolli holds an undergraduate degree in engineering from Princeton University and a medical degree from the University of Utah College of Medicine.

Nov 18, 2020

PierianDx: Mark McDonough

PierianDx has hired Mark McDonough as CEO. McDonough, who has also joined the company's board of directors, takes over from Chairman and interim CEO Joe Boorady. The previous permanent CEO, Michael Sanderson, left PierianDx in April. McDonough previously was president and CEO of immunogenomics startup Immunis.AI. He also led CombiMatrix through that firm's 2017 acquisition by Invitae.

Nov 18, 2020

Quanterix: William Geist

Quanterix has named William Geist as chief operating officer. Geist most recently served as vice president and general manager for two of Thermo Fisher Scientific's protein and cell analysis and qPCR business units. He also held a key leadership role in Thermo Fisher's COVID-19 task force in its biosciences division. Prior to this, Geist held numerous sales, marketing, and business development leadership roles including vice president of sales, marketing, and business development at Qiagen's Quanta BioSciences. He holds a BA in biology from Dartmouth College.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.